Date published: 2026-4-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

S-Trityl-L-cysteine (CAS 2799-07-7)

5.0(1)
Write a reviewAsk a question

See product citations (6)

Application:
S-Trityl-L-cysteine is a cell-permeable selective inhibitor of mitotic kinesin Eg5 and ATPase activities
CAS Number:
2799-07-7
Purity:
>98%
Molecular Weight:
363.5
Molecular Formula:
C22H21NO2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

S-Trityl-L-cysteine is a cell-permeable cysteine thioether compound that exhibits antitumor and antimitotic properties by inhibiting mitotic kinesin Eg5. S-Trityl-L-cysteine has been found to potently block that basal and microtubule-activated mitotic spindle kinesin ATPase activities. S-Trityl-L-cysteine may act to be 36-fold more potent than Monastrol (sc-202710) for inducing mitotic arrest in HeLa cells.


S-Trityl-L-cysteine (CAS 2799-07-7) References

  1. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.  |  DeBonis, S., et al. 2004. Mol Cancer Ther. 3: 1079-90. PMID: 15367702
  2. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.  |  Brier, S., et al. 2004. Biochemistry. 43: 13072-82. PMID: 15476401
  3. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.  |  Skoufias, DA., et al. 2006. J Biol Chem. 281: 17559-69. PMID: 16507573
  4. Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5.  |  Kozielski, F., et al. 2008. Proteomics. 8: 289-300. PMID: 18186019
  5. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.  |  Debonis, S., et al. 2008. J Med Chem. 51: 1115-25. PMID: 18266314
  6. Biochemical analysis of cellular target of S-trityl-L-cysteine derivatives using affinity matrix.  |  Shimizu, M., et al. 2010. Bioorg Med Chem Lett. 20: 1578-80. PMID: 20138511
  7. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.  |  Wiltshire, C., et al. 2010. Mol Cancer Ther. 9: 1730-9. PMID: 20515952
  8. S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line.  |  Shimizu, M., et al. 2010. Cancer Lett. 298: 99-106. PMID: 20619960
  9. Inhibition of hepatitis C virus NS5B polymerase by S-trityl-L-cysteine derivatives.  |  Nichols, DB., et al. 2012. Eur J Med Chem. 49: 191-9. PMID: 22280819
  10. Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine.  |  Abualhasan, MN., et al. 2012. Eur J Med Chem. 54: 483-98. PMID: 22749640
  11. Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models.  |  Good, JA., et al. 2013. J Med Chem. 56: 1878-93. PMID: 23394180
  12. Photocontrol of the mitotic kinesin Eg5 using a novel S-trityl-L-cysteine analogue as a photochromic inhibitor.  |  Ishikawa, K., et al. 2014. J Biochem. 155: 257-63. PMID: 24451491
  13. S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.  |  Wu, W., et al. 2018. Oncol Lett. 16: 1023-1030. PMID: 29963178
  14. Antiproliferative S-Trityl-l-Cysteine -Derived Compounds as SIRT2 Inhibitors: Repurposing and Solubility Enhancement.  |  Radwan, MO., et al. 2019. Molecules. 24: PMID: 31510043
  15. Design, synthesis, and evaluation of a novel prodrug, a S-trityl-l-cysteine derivative targeting kinesin spindle protein.  |  Fukai, R., et al. 2021. Eur J Med Chem. 215: 113288. PMID: 33640763

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

S-Trityl-L-cysteine, 1 g

sc-202799
1 g
$32.00

S-Trityl-L-cysteine, 5 g

sc-202799A
5 g
$66.00